Abstract: Compositions and methods for reducing ocular diseases by implanting in an eye of a subject a composition comprising encapsulated cells which produce polypeptides, more particularly polypeptides that exhibit neurotrophic and/or anti-angiogenic activity. The encapsulation prevents the entry of host immune cells in the microcapsule while permitting the release of the polypeptide outside of the microcapsule.
Type:
Grant
Filed:
February 1, 2001
Date of Patent:
December 16, 2003
Assignees:
Universite de Paris V Rene-Descartes, Association Francaise Retinitis Pigmentosa
Inventors:
Marc Abitbol, Yves Uteza, Maurice Menasche, Carine Bossard, Loic Van Den Berghe, Sebastian Bonnel, Hervé Prats, Jiri Honiger, Martin Neuner-Jehle
Abstract: Compositions and methods for reducing ocular diseases by implanting in an eye of a subject a composition comprising encapsulated cells which produce polypeptides, more particularly polypeptides that exhibit neurotrophic and/or anti-angiogenic activity. The encapsulation prevents the entry of host immune cells in the microcapsule while permitting the release of the polypeptide outside of the microcapsule.
Type:
Grant
Filed:
February 1, 2001
Date of Patent:
December 31, 2002
Assignees:
Universite de Paris V Rene-Descartes, Association Francaise Retinitis Pigmentosa
Inventors:
Marc Abitbol, Yves Uteza, Maurice Menasche, Carine Bossard, Loïc Van Den Berghe, Sébastian Bonnel, Hervé Prats, Jiri Honiger, Martin Neuner-Jehle
Abstract: Compositions and methods for reducing ocular diseases by implanting in an eye of a subject a composition comprising encapsulated cells which produce polypeptides, more particularly polypeptides that exhibit neurotrophic and/or anti-angiogenic activity. The encapsulation prevents the entry of host immune cells in the microcapsule while permitting the release of the polypeptide outside of the microcapsule.
Type:
Application
Filed:
February 1, 2001
Publication date:
June 20, 2002
Applicant:
Universite de Paris V Rene-Descartes
Inventors:
Marc Abitbol, Yves Uteza, Maurice Menasche, Carine Bossard, Loic Van Den Berghe, Sebastian Bonnel, Herve Prats, Jiri Honiger, Martin Neuner-Jehle
Abstract: Compositions and methods for reducing ocular diseases by implanting in an eye of a subject a composition comprising encapsulated cells which produce polypeptides, more particularly polypeptides that exhibit neurotrophic and/or anti-angiogenic activity. The encapsulation prevents the entry of host immune cells in the microcapsule while permitting the release of the polypeptide outside of the microcapsule.
Type:
Application
Filed:
February 1, 2001
Publication date:
June 20, 2002
Applicant:
Universite de Paris V Rene-Descartes
Inventors:
Marc Abitbol, Yves Uteza, Maurice Menasche, Carine Bossard, Loic Van Den Berghe, Sebastian Bonnel, Herve Prats, Jiri Honiger, Martin Neuner-Jehle
Abstract: Compositions and methods for reducing ocular diseases by implanting in an eye of a subject a composition encapsulated cells which produce polypeptides, more particularly polypeptides that exhibit neurotrophic and/or anti-anglogenic activity. The encapsulation prevents the entry of host immune cells in the microcapsule while permitting the release of the polypeptide outside of the microcapsule.
Type:
Grant
Filed:
November 24, 1999
Date of Patent:
July 31, 2001
Assignees:
Universite de Paris V Rene-Descartes, Association Francaise Retinitis Pigmentosa
Inventors:
Marc Abitbol, Yves Uteza, Maurice Menasche, Carine Bossard, Loïc Van Den Berghe, Sébastien Bonnel, Hervé Prats, Jiri Honiger, Martin Neuner-Jehle
Abstract: This medicinal composition for the treatment and prevention of the symptoms of heart failure contains, by way of active principle, at least one compound chosen from 2-amino-1-(2,5-dimethoxyphenyl)-1-propanol (methoxamine) and its pharmaceutically acceptable salts, and it is presented in a form which can be administered by inhalation (aerosol or nebulizate).It was demonstrated, in particular, that the administration of methoxamine-HCl by inhalation, at a unit dosage of 10 mg, in the form of a 2% (w/v) solution in physiological saline, decreases airways resistance in subjects suffering from decompensated left ventricular failure, and increases the exertion tolerance of patients suffering from compensated left vetricular failure, whether the latter is of ischemic origin or otherwise.
Type:
Grant
Filed:
June 14, 1989
Date of Patent:
May 26, 1992
Assignee:
Universite de Paris V
Inventors:
Laure Cabanes, Alain Lockhart, Simon Weber